Home/Pipeline/NS-0100

NS-0100

Undisclosed Oncology

PreclinicalResearch

Key Facts

Indication

Undisclosed Oncology

Phase

Preclinical

Status

Research

Company

Nippon Shinyaku

About Nippon Shinyaku

Nippon Shinyaku is a well-established, revenue-generating Japanese pharmaceutical company with a strategic focus on creating novel treatments for unmet medical needs. Its commercial success is anchored by Viltepso, an exon-skipping therapy for Duchenne muscular dystrophy, alongside other marketed products. The company leverages its research expertise to advance a pipeline spanning rare genetic diseases, oncology, and metabolic conditions, aiming for sustainable growth through both internal R&D and strategic partnerships.

View full company profile

Therapeutic Areas

Rare Diseases Neuromuscular Disorders Hematology Metabolic Disorders Oncology

Other Undisclosed Oncology Drugs

Drug	Company	Phase	Status
PPS-001	PeptiDream	Preclinical	Active
BRM Selective Program	Foghorn Therapeutics	Discovery	Internal Program